What is ADMA Biologics's pre-tax income?

ADMA Biologics (ADMA) reported pre-tax income of $57.13M in Q1 2026.

How has ADMA Biologics's pre-tax income changed year-over-year?

ADMA Biologics's pre-tax income increased by 70.8% year-over-year, from $33.45M to $57.13M.

What is the long-term trend for ADMA Biologics's pre-tax income?

Over 3 years (2022 to 2025), ADMA Biologics's pre-tax income has grown at a 40.5% compound annual growth rate (CAGR), from -$65.9M to $182.66M.

What does pre-tax income mean?

Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

ADMA Biologics ADMA Pre-Tax Income

Pre-Tax Income at other companies

AbCellera Biologics Inc.ABCL

-$49.54M+6.5%

AnaptysBio, Inc.ANAB

-$52.84M-34.5%

ZymeworksZYME

-$46.35M-109%

Bio-Rad LaboratoriesBIO

-$689.8M-927%

Apogee Therapeutics, Inc.APGE

-$74.03M-34.0%

Quest DiagnosticsDGX

$334M+21.0%

Segments

By segment

See full

ADMA Bio Manufacturing$62.3M+37.8%

Plasma Collection Centers$6.91M+882%

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's pre-tax income?: ADMA Biologics (ADMA) reported pre-tax income of $57.13M in Q1 2026.
How has ADMA Biologics's pre-tax income changed year-over-year?: ADMA Biologics's pre-tax income increased by 70.8% year-over-year, from $33.45M to $57.13M.
What is the long-term trend for ADMA Biologics's pre-tax income?: Over 3 years (2022 to 2025), ADMA Biologics's pre-tax income has grown at a 40.5% compound annual growth rate (CAGR), from -$65.9M to $182.66M.
What does pre-tax income mean?: Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.